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ABSTRACT 
Objective: The present work describes the development and subsequent validation of a simple, precise and stability–indicating reversed-phase 
high-performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of diethylcarbamazine citrate, guaiphenesin and 
chlorpheniramine maleate in tablet dosage forms. 
Methods: A simple, accurate, precise and robust RP-HPLC method was developed and validated for the estimation of diethylcarbamazine citrate, 
guaiphenesin and chlorpheniramine maleate. The chromatographic separation of all the three active components was achieved by using luna 
phenyl-hexyl column (250 mmx4.6 mm, dp=5 µm) with a mobile phase consisting of isocratic method with 0.1% triethylamine as buffer along with 
orthophosphoric acid adjusted to PH
Results: The retention time of chlorpheniramine maleate, guaiphenesin and diethylcarbamazine citrate were 2.86, 4.89 and 7.76 min respectively. 
Validation of the proposed method was carried out according to an international conference on harmonization (ICH) guidelines. The established 
method was linear in the range of 1-15, 0.6-9, 0.02-0.3 µg/ml and correlation coefficient was 0.999, 0.9991, and 0.993 for diethylcarbamazine 
citrate, guaiphenesin and chlorpheniramine maleate respectively. 
 2.5: acetonitrile (50:50v/v) at a flow rate 1.0 ml/min and ultraviolet detection at 210 nm. 
Conclusion: The proposed method can be used for the quantitative analysis of diethylcarbamazine citrate, guaiphenesin and chlorpheniramine maleate.  
Keywords: Diethylcarbamazine citrate, Guaiphenesin and Chlorpheniramine maleate 




Diethylcarbamazine citrate, chemically N, N-diethyl-4-methyl 
piperazine-1-carboxamide dihydrogen citrate [1] is one of the essential 
medicines needed in a basic health system, suggested by world health 
organisation (WHO) [2]. It is used in the treatment of filariasis including 









Fig. 1: Chemical structure of diethylcarbamazine citrate 
 
Guaiphenesin, chemically (S, S)-2-methlylamino-1-phenylpropan-1-
ol hydrochloride [3, 4], mainly used as a cough remedy. It has been 
given to patients which have altered nasal mucociliary clearance 
associated with HIV. It is used to remove phlegm from the airways in 







Fig. 2: Chemical structure of guaiphenesin 
 
As chlorpheniramine maleate, chemically (RS)-3-(4-chlorophenyl)-
3-(pyrid-2-yl) propyl dimethylamine hydrogen maleate [5], has the 
relatively less sedative effect it is most commonly used as an 










HOOC COOH  
Fig. 3: Chemical structure of chlorpheniramine maleate 
 
The literature survey revealed that several analytical methods have 
been reported for the estimation of diethylcarbamazine citrate [6], 
guaiphenesin [7] and chlorpheniramine maleate [8, 9] individually 
or in combination with other drugs by UV-visible spectro-
photometry, nuclear magnetic resonance spectroscopy, high-
performance liquid chromatography methods [10-13]. No method 
has been developed for the simultaneous determination of 
diethylcarbamazine citrate, guaiphenesin, chlorpheniramine maleate 
both in bulk and pharmaceutical dosage forms. 
On the meticulous observance of the potential applications of these 
three active drugs, we aimed to develop and validate a new, rapid 
and sensitive RP-HPLC method for simultaneous estimation of 
diethylcarbamazine citrate, guaiphenesin, and chlorpheniramine 
maleate. Degradation studies (stress studies) were carried out to 
establish the stability characteristics of the three ingredients under 
heat, acid, base, peroxide, light and reductive stress conditions as 
recommended in the ICH guidelines Q1A (R2). 
MATERIALS AND METHODS  
Instrumentation 
The analysis was performed on waters alliance-2695 chromato-
graphic system, equipped with a quaternary pump and PDA 
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detector-2996. Chromatographic software empower-2.0 was used 
for data collection and processing. 
Chemicals and reagents 
Acetonitrile (HPLC grade), triethylamine (HPLC grade), orthophophoric 
acid (HPLC grade), water (HPLC grade) were purchased from Merk 
(India) Ltd, Worli, Mumbai, India. All active pharmaceutical ingredients 
(APIs) of diethylcarbamazine citrate, guaiphenesin and chlor-
pheniramine maleate as reference standards were procured from 
Supriya life Sciences, Goregaon (E), Mumbai, India (99.7-99.9 % purity). 
Chromatographic conditions 
Chromatographic analysis was done using isocratic elution and 
acetonitrile: 0.1% triethylamine PH
Selection of wavelength  
 adjusted to 2.5 with OPA (50:50 
by volume) as a mobile phase and was filtered through 0.45µ 
membrane filter paper. The flow rate of the mobile phase was 
monitored at 1 ml/min and eluents were detected at 210 nm. 
Operating pressure 3000 psi was maintained at room temperature 
by injecting the volume 10 µl with a run time 10 min. 
By using photodiode spectrophotometer the absorption spectra of 
the solution of the three drugs in acetonitrile were scanned in the UV 
region 200-400 nm against acetonitrile as blank and spectra are 
shown in fig. From the fig. the spectra of the diethylcarbamazine 
citrate, guaiphenesin and chlorpheniramine maleate shows different 
λmax viz. 254.5, 255.6 and 369.4 nm respectively. By considering the 
chromatographic parameter, sensitivity and selectivity of a method 
for three drugs 210 nm was selected as the detection wavelength for 
HPLC chromatographic method. 
 
 
Fig. 4: PDA spectrum for diethylcarbamazine citrate, guaiphenesin and chlorpheniramine maleate 
 
Preparation of standard solution 
100 mg of diethylcarbamazine citrate, 60 mg of guaiphenesin, 2 mg 
of Chlorpheniramine maleate (working standard) were weighed 
accurately and transferred into a 100 ml volumetric flask.70 ml of 
mobile phase was added to the above flask and then sonicated about 
20 min for uniform mixing and then diluted 1 ml of the above 
solution to 10 ml with the mobile phase and again 1 ml of the 
solution was diluted to 10 ml with same mobile phase. 
Preparation of sample solution 
10 tablets were weighed and pulverised to powder form, from which 
one equivalent weight (437.5 mg) was taken into 100 ml volumetric 
flask.70 ml of mobile phase was added to the above flask and then 
sonicated about 20 min for uniform mixing. 1 ml of the above 
solution was diluted to 100 ml with the mobile phase and filtered 
through 0.45μ nylon syringe filter. 
Validation  
The optimized chromatographic separation was aimed to obtain a 
resolution above 1.5 between all components, tailing factor is less 
than 2.0 and plate count will be more than 2000 with respect to the 
stationary, mobile phase compositions, flow rate, sample volume, 
detection wavelength and temperature. 
Validation procedure 
In the present method validation was done with the aspect of system 
suitability, specificity, accuracy, precision, linearity, robustness, limit 
of detection (LOD), limit of quantitation (LOQ), forced degradation 
and stability according to the ICH guidelines [14-18]. 
  
 
Fig. 5: Typical chromatogram for diethylcarbamazine citrate, guaiphenesin and chlorpheniramine maleate 
Rao et al. 
Int J App Pharm, Vol 10, Issue 1, 2018, 124-135 
 
126 
System suitability  
As per the test method the standard and check standard solutions 
were prepared and injected into HPLC system [10, 11], from which 
the evaluated system suitability parameters are found to be within 
the limits. 
Specificity  
The analyte was assessed unequivocally to know the components 
impurity which may be expected to be present with the help of 
specificity. As per test method blank was prepared and injected. No 
blank peak was eluted in the retention time of analyte peak. Placebo 
solutions were prepared in duplicate and injected as per test 
method. It was found that no placebo peaks were interfered at the 
retention time of the main peak.  
Accuracy 
Three different concentrations such as lower quantitation limit, 
medium quantitation limit, and higher quantitation limit were used 
to evaluate the accuracy of the RP-HPLC method. The amount of the 
drugs present, percentage recovery and RSD were calculated by 
giving a minimum of three injections from each concentration.  
Precision 
The precision of the test method was evaluated by considering six 
different concentrations. The amount of the drugs present, 
percentage recovery and RSD were calculated by giving a minimum 
of six preparations. 
Linearity and range 
Six series of standard solutions were selected for assessing linearity 
range. By using peak area versus concentration of the standard 
solution calibration curve was plotted and the regression equations 
were also calculated. The slope, intercept and the correlation 
coefficient was calculated by least squares method.  
LOD and LOQ 
By using optimized chromatographic conditions in accordance with 
3.3 s/n and 10 s/n criteria, where s/n indicates signal-to-noise ratio, 
the LOD and LOQ were determined by injecting progressively lower 
concentrations of the standard solutions into the HPLC column.  
Forced degradation 
In chromatogram of forced degradation there should be no 
interference between peaks and were well separated from each 
other with the resolution at least 1.0 and the peak purity of the 
principal peaks should pass. Forced degradation studies were 
performed by different types of stress conditions to obtain the 
degradation of about 20%. 
Robustness 
Small changes such as±5% in the ratio of acetonitrile in the mobile 
phase,±0.2 ml/min in the flow rate and±5 nm in the wavelength 
were made to demonstrate the robustness method. The separation 
factor, retention time and peak asymmetry were calculated. 
Stability 
Standard and the sample solutions were subjected to 24 h stability 
studies. The stability of these solutions was studied and observed for 
changes in the area and retention time of the peaks which were then 
compared with the pattern of the chromatogram of the freshly 
prepared solution. 
RESULTS AND DISCUSSION  
Method validation 
In this method system suitability, linearity, precision, accuracy, 
robustness, LOD (Limit detection), LOQ (Limit of quantification), 
forced degradation and the stability are validated for the selected 
diethylcarbamazine citrate, guaiphenesin and chlorpheniramine 
maleate drugs. 
System suitability  
10 µl of working standard solution (10µg/ml of diethylcarbamazine 
citrate, 6µg/ml of guaiphenesin and 0.2µg/ml of chlorpheniramine 
maleate) was prepared and injected into the system. It was 
determined by making six replicate injections and all the parameters 
were found to be within the limits. The results are given table 1. 
 
Table 1: System suitability parameters for diethylcarbamazine citrate, guaiphenesin and chlorpheniramine maleate 
System suitability parameter Diethylcarbamazine citrate Guaiphenesin Chlorpheniramine maleate 
Retention time (min) 7.850 4.715 2.900 
Theoretical plate number (N) 10909 4416 5810 
Tailing factor (T) 1.062 1.145 1.271 
Resolution (R) 10.693 8.386 - 
 
Linearity 
The linearity of the proposed method was constructed by 
considering concentration on the x-axis and peak area on the y-axis. 
It was established by least squares linear regression analysis of the 
calibration curve. The calibration curve was linear in the range of 1-
15, 0.6-9, 0.02-0.3 µg/ml for diethylcarbamazine citrate, 
guaiphenesin and chlorpheniramine maleate respectively. The 
regression equation for calibration curve was Y=561967x+13655 
(r2=0.999) for diethylcarbamazine citrate, Y=474141x+21692 
(r2=0.999) for guaiphenesin and Y=951864x+4648 (r2
 
=0.999) for 
chlorpheniramine maleate. The results are given in table 2. 
Table 2: Linearity data for diethylcarbamazine citrate, guaiphenesin and chlorpheniramine maleate 
Diethylcarbamazine citrate Guaiphenesin Chlorpheniramine maleate 
Conc µg/ml Area counts Conc µg/ml Area counts Conc µg/ml Area counts 
1.00 560581 0.60 278415 0.02 190320 
2.50 1419062 1.50 687456 0.05 487956 
5.00 2878887 3.00 1358742 0.10 954786 
10.00 5602579 6.00 2786284 0.20 1923654 
12.50 7041847 7.50 3568745 0.25 2378462 
15.00 8443101 9.00 4254810 0.30 2854810 
Corr Coef 0.999 Corr Coef 0.999 Corr Coef 0.999 
Slope 561966.74 Slope 474141.22 Slope 9518964.73 
Intercepst 13655.29 Intercept 21692.26 Intercept 4648.64 
Rao et al. 




Fig. 6: Chromatogram for linearity-1 
 
 
Fig. 7: Chromatogram for linearity-2 
 
 
Fig. 8: Chromatogram for linearity-3 
 
 
Fig. 9: Chromatogram for linearity-4 
 
 
Fig. 10: Chromatogram for linearity-5 
 
Fig. 11: Chromatogram for linearity-6 
 
 
Fig. 12: Linearity plot for diethylcarbamazine citrate 
 
 
Fig. 13: Linearity plot for guaiphenesin 
 
.  
Fig. 14: Linearity plot for chlorpheniramine maleate 
 
Accuracy 
In this method, accuracy was determined by recovery studies which 
were carried out in three different concentration levels (50%, 100% 
and 150%). APIs with concentration 5, 10 and 15 µg/ml of 
diethylcarbamazine citrate; 3, 6 and 9 µg/ml of guaiphenesin; and 0.1, 
0.2 and 0.3 µg/ml of chlorpheniramine maleate were prepared. As per 
the test method, the test solution was injected three times for each 
spike level and the assay was performed. The accuracy and reliability 
of the developed method were established. The percentage recovery 
values were found to be in the range of 100.34-100.81% for 
diethylcarbamazine citrate and 100.51-100.18% for guaiphenesin and 
100.64-100.34% for chlorpheniramine maleate. RSD values were 
found to be less than 2%. The results are given in table 3, 4 and 5. 
 
Rao et al. 
Int J App Pharm, Vol 10, Issue 1, 2018, 124-135 
 
128 
Table 3: Accuracy data for diethylcarbamazine citrate 






Area counts % Recovery Mean recovery, 
±RSD 
50% 10.01 5.08 5.031 1383585 100.34 100.26, 
0.10 10.01 5.04 5.012 1379603 100.28 
10.01 5.11 5.143 1313241 100.15 
100% 10.01 10.18 10.541 2789315 100.27 100.26, 
0.07 10.01 10.12 10.324 2784571 100.18 
10.01 10.16 10.148 2799874 100.32 
150% 10.01 15.47 15.478 4189106 100.24 100.5 
0.28 10.17 15.28 15.369 4196329 100.45 
10.17 15.19 15.214 4145316 100.81 
 
Table 4: Accuracy data for guaiphenesin 






Area counts % Recovery Mean recovery, 
±RSD 
50% 6.12 3.01 3.124 904105 100.51 100.37, 
0.12 6.12 3.05 3.131 904979 100.35 
6.12 3.14 3.214 894400 100.27 
100% 6.12 6.15 6.528 1871153 100.38 100.45, 
0.07 6.12 6.21 6.374 1880820 100.47 
6.12 6.28 6.484 1892189 100.52 
150% 6.12 9.57 9.428 2847220 100.61 100.42, 
0.21 6.12 9.26 9.569 2867896 100.48 
6.12 9.15 9.214 2816024 100.18 
 
Table 5: Accuracy data for chlorpheniramine maleate 






Area counts % Recovery Mean recovery, 
±RSD 
50% 0.21 0.15 0.148 254967 100.64 100.49, 
0.19 0.21 0.14 0.142 257431 100.58 
0.21 0.11 0.147 252908 100.27 
100% 0.21 0.21 0.215 547450 100.56 100.41, 
0.13 0.21 0.22 0.218 546146 100.38 
0.21 0.23 0.223 541044 100.29 
150% 0.21 0.30 0.347 793703 100.17 100.24, 
0.08 0.21 0.31 0.311 792084 100.21 
0.21 0.32 0.318 793544 100.34 
 
 
Fig. 15: Chromatogram for accuracy 50%-1 
 
 
Fig. 16: Chromatogram for accuracy 50%-2 
 
 
Fig. 17: Chromatogram for accuracy 50%-3 
 
 
Fig. 18: Chromatogram for accuracy 100%-1 
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Fig. 19: Chromatogram for accuracy 100%-2 
 
 
Fig. 20: Chromatogram for accuracy 100%-3 
 
 
Fig. 21: Chromatogram for accuracy 150%-1 
 
 
Fig. 22: Chromatogram for accuracy 150%-2 
 
 
Fig. 23: Chromatogram for accuracy 150%-3 
Precision 
Repeatability 
Repeatability was calculated by injecting standard solution six times 
containing diethylcarbamazine citrate (10µg/ml), guaiphenesin 
(6µg/ml) and chlorpheniramine maleate (0.2µg/ml). Peak areas and 
% RSD were calculated. 
Intraday precision 
Six replicates of a sample solution containing diethylcarbamazine 
citrate (10µg/ml), guaiphenesin (6µg/ml) and chlorpheniramine 
maleate (0.2µg/ml) were analysed on the same day. Peak areas were 
calculated, which were used to calculate mean, SD and %RSD values.  
Interday precision 
Six replicates of a sample solution containing diethylcarbamazine 
citrate (10µg/ml), guaiphenesin (6µg/ml), and chlorpheniramine 
maleate (0.2µg/ml) were analysed on a different day. Peak areas 
were calculated which were used to calculate mean, SD and %RSD 
values. The present method was found to be precise as the RSD 
values were less than 2% and also the percentage assay values were 
close to be 100%. The results are given in table 6 and 7. 
 
 
Fig. 24: Chromatogram for method precision-1 
 
 
Fig. 25: Chromatogram for method precision-2 
 
 
Fig. 26: Chromatogram for method precision-3 
 
Table 6: Intraday data for diethylcarbamazine citrate, guaiphenesin and chlorpheniramine maleate 
Diethylcarbamazine citrate Guaiphenesin Chlorpheniramine maleate 
Conc (µg/ml) Area counts % assay as is Conc (µg/ml) Area counts % assay as is Conc (µg/ml) Area counts % assay as is 
10.0 2789315 100.42 6.0  1871153 100.68 0.2  547450 100.25 
2788941 100.68  1880820 100.54  541665 100.37 
2764650 100.54 1892189  100.42 549553  100.48 
 2790843 100.28 1892461  100.37 546337  100.51 
2789315 100.64 1871153  100.26 547450  100.68 
2789421 100.37 1892189  100.15 545149  100.75 
% RSD 1.66 0.67 0.49 
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Table 7: Interday data for diethylcarbamazine citrate, guaiphenesin and chlorpheniramine maleate 
Diethylcarbamazine citrate Guaiphenesin Chlorpheniramine maleate 
Conc (µg/ml) Area counts % assay 
as is 
Conc (µg/ml) Area counts % assay 
as is 
Conc (µg/ml) Area counts % assay 
as is 
10.0  2764851 100.56 6.0  1841523 100.43 0.2  541282  100.38 
 2758945 100.37  1847456 100.68  541365  100.56 
 2768748 100.41 1848752  100.36 541878 100.37 
2775358 100.52 1845896  100.38 541758 100.58 
2787486 100.78 1847893  100.55 541785 100.41 
2778952 100.54 1847895  100.47 541478 100.36 
% RSD 0.84 0.73 0.68 
 
 
Fig. 27: Chromatogram for method precision-4 
 
 
Fig. 28: Chromatogram for method precision-5 
 
 
Fig. 29: Chromatogram for method precision-6 
 
 
Fig. 30: Chromatogram for intermediate precision-1 
 
Fig. 31: Chromatogram for intermediate precision-2 
 
 
Fig. 32: Chromatogram for intermediate precision-3 
 
 
Fig. 33: Chromatogram for intermediate precision-4 
 
LOD and LOQ 
LOD and LOQ minimum concentration level at which the analyte can 
be reliably detected, quantified by using the standard formulas 
(3.3times σ/s and 10times σ/s for LOD and LOQ respectively) were 
found to be 0.1 and 0.2 µg/ml for diethylcarbamazine citrate, 0.06 
and 0.12 µg/ml for guaiphenesin and 0.002 and 0.004 µg/ml for 
chlorpheniramine maleate. The low values of LOD and LOQ indicate 
the high sensitivity of method. The results are given in table 8 and 9. 
 
Table 8: Results of LOQ 
Diethylcarbamazinecitrate Guaiphenesin Chlorpheniramine maleate 
Conc (µg/ml) s/n Conc (µg/ml) s/n Conc  (µg/ml) s/n 
0.2 17 0.12 15 0.004 18 
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Table 9: Results of LOD 
Diethylcarbamazine citrate Guaiphenesin Chlorpheniramine maleate 
Conc (µg/ml) s/n Conc (µg/ml) s/n Conc (µg/ml) s/n 
0.1 5 0.06 4 0.002 6 
 
 
Fig. 36: Chromatogram for LOD 
 
 
Fig. 37: Chromatogram for LOQ 
 
Forced degradation 
Stress degradation conditions such as acidic, basic, oxidative, 
reduction, thermal, hydrolysis and photolytic stresses were 
attempted as per ICH guidelines Q1A (R2).  
Acid degradation  
Acid degradation studies were carried out by weighing 27 mg of 
sample and transferred to a 10 ml volumetric flask, to this add 5 
ml of diluent dissolve it and add 0.1 ml of 5N HCl. The mixture 
was refluxed at 70 °C for 1 hour. Then the solution was 
neutralized with 0.1 ml of 5N NaOH and diluted with the mobile 
phase up to the mark and mixed well. 0.1 ml of the same solution 
was diluted to 10 ml with the diluent. 10 µl of the above solution 
was injected into the HPLC system and chromatograms were 
recorded.  
Alkali degradation 
Alkali degradation studies were carried out by weighing 27 mg of 
sample and transferred to a 10 ml volumetric flask, to this add 5 ml 
of diluent dissolve it and add 0.1 ml of 5N NaOH. The mixture was 
refluxed at 70 °C for 1 hour. Then the solution was neutralized with 
0.1 ml of 5N HCl and diluted with the mobile phase up to the mark 
and mixed well. 0.1 ml of the same solution was diluted to 10 ml 
with the diluent. 10 µl of the above solution was injected into the 
system and chromatograms were recorded.  
Peroxide degradation  
Peroxide degradation studies were carried out by weighing 27 mg of 
sample and transferred to a 10 ml volumetric flask, to this add 5 ml 
of diluent dissolve it and add 0.1 ml of 15% H2O2. 
Reduction degradation  
Reduction degradation studies were carried out by weighing 27 mg 
of sample and transferred to a 10 ml volumetric flask, to this add 5 
ml of diluent dissolve it and add 0.1 ml of 10% sodium bisulphate. 
The mixture was refluxed at 70 °C for 1 hour. 0.1 ml of the same 
solution was diluted to 10 ml with the diluent. 10 µl of the above 
solution was injected into the system and chromatograms were 
recorded.  
Hydrolysis degradation:  
Hydrolysis degradation studies were carried out by weighing 27 
mg of sample and transferred to a 10 ml volumetric flask, to this 
add 5 ml of diluent and add 0.1 ml of water and sonicated to 
disperse, dissolve and refluxed at 70 °C for 30 min. 0.1 ml of the 
same solution was diluted to 10 ml with the diluent. 10 µl of the 
above solution was injected into the system and chromatograms 
were recorded. 
Thermal degradation  
Thermal degradation studies were carried out by weighing 27 
mg of sample and exposed to a temperature of 80 °C for 72 h in 
hot air oven. Then the sample was transferred to a 10 ml 
volumetric flask, dissolves in 5 ml of diluent and diluted with 
mobile phase up to the mark. 1 ml of the same solution was 
diluted to 10 ml with the diluent. 10 µl of the above solution was 
injected into the system and chromatograms were recorded. 
Photolytic degradation  
The mixture was 
refluxed at 70 °C for 30 min.1 ml of the same solution was diluted to 
10 ml with the diluent. 10 µl of the above solution was injected into 
the system and chromatograms were recorded.  
Photolytic degradation studies were carried out by weighing 27 
mg of sample and exposed to 1.2 Million lux hours of light. Then 
the sample was transferred to a 10 ml volumetric flask, dissolved 
in 5 ml of diluent and diluted with the mobile phase up to the 
mark. 1 ml of the same solution was diluted to 10 ml with the 
diluent.10 µl of the above solution was injected into the system 
and chromatograms were recorded. 
 
Table 10: Results of force degradation studies of diethylcarbamazine citrate 
Stress condition Time % assay % degradation Purity angle Purity threshold 
Acid degradation 1h 86.8 13.2 0.12 0.25 
Alkaline degradation 1h 94.8 5.2 0.14 0.28 
Oxidative degradation 30 min 96.5 3.5 0.18 0.24 
Reduction degradation 1h 93.6 6.4 0.16 0.30 
Thermal degradation 3h 87.2 12.8 0.14 0.28 
Photolytic degradation 72h 84.9 15.1 0.11 0.25 
Hydrolysis degradation 30 min 91.1 8.9 0.15 0.24 
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Table 11: Results of force degradation studies of guaiphenesin 
Stress condition Time % assay % degradation Purity  angle Purity threshold 
Acid degradation 1h 85.4 14.6 0.10 0.27 
Alkaline degradation 1h 93.6 6.4 0.17 0.32 
Oxidative degradation 30 min 95.3 4.7 0.23 0.37 
Reduction degradation 1h 92.7 7.3 0.24 0.36 
Thermal degradation 3h 86.5 13.5 0.25 0.45 
Photolytic degradation 72h 84.2 15.8 0.16 0.28 
Hydrolysis degradation 30 min 91.8 8.2 0.18 0.39 
 
Table 12: Results of force degradation studies of chlorpheniramine maleate 
Stress condition Time % assay % degradation Purity angle Purity threshold 
Acid degradation 1h 85.4 13.7 0.14 0.34 
Alkaline degradation 1h 93.6 5.8 0.17 0.36 
Oxidative degradation 30 min 95.3 4.2 0.25 0.39 
Reduction Degradation 1h 92.7 7.5 0.19 0.42 
Thermal degradation 3h 86.5 12.8 0.23 0.41 
Photolytic Degradation 72h 84.2 16.4 0.18 0.51 
Hydrolysis Degradation 30 min 91.8 9.4 0.15 0.43 
 
 
Fig. 38: Chrom for acid degradation 
 
 
Fig. 39: Chrom for alkali degradation 
 
 
Fig. 40: Chrom for peroxide degradation 
 
 
Fig. 41: Chrom for reduction degradation 
 
Fig. 42: Chrom for thermal degradation 
 
 
Fig. 43: Chrom for photolytic degradation 
 
 
Fig. 44: Chrom for hydrolysis degradation 
 
Robustness 
The proposed method was found to be Robust as the % RSD was found 
to be less than 2%. Slight variations were done in the optimised method 
parameters like flow rate (±0.2%), organic content in mobile phase 
(±5%), pH (±0.2) and wavelength of detection (±5%).  
Flow rate variation 
This study was conducted to find the effect of variation in flow rate. 
Standard and check standard solutions were prepared as per test 
Rao et al. 
Int J App Pharm, Vol 10, Issue 1, 2018, 124-135 
 
133 
method and injected into HPLC system with a flow rate of 1.0 
ml/min. System suitability parameters were evaluated and found to 
be within the specified limits as per test method and RT of the main 
peak was monitored. 
Organic phase variation 
This study was conducted to find the effect of variation in organic 
phase. Standard and check standard solutions were prepared as per 
the test method and injected into HPLC system with mobile phases 
of 0.1% triethylamine as a buffer along with orthophosphoric acid 
adjusted to PH
PH variation 
 2.5: acetonitrile(50:50v/v) and wavelength of 210 
nm. System suitability parameters are found to be within the 
specified limits and RT of the main peak was monitored for 50:50 
v/v (mixed 0.1% triethylamine buffer). 
This study was conducted to find the variation in PH. Standard and 
check standard solutions were prepared as per test method and 
injected into HPLC system with different buffer PH
Wavelength variation 
. System suitability 
parameters were evaluated and found to be within the specified 
limits as per test method and RT of the main peak was monitored. 
This study was conducted to find the effect of variation in 
wavelength. Standard and check standard solutions were prepared 
as per test method and injected into HPLC system with different 
buffer wavelengths. System suitability parameters were evaluated 
and found to be within the specified limits as per test method and RT 
of the main peak was monitored. 
 
Table 13: Results for robustness 
Parameter Diethylcarbamazine citrate Guaiphenesin Chlorpheniramine maleate 
USP plate count USP tailing USP plate count USP tailing USP plate count USP tailing 
Less flow rate (0.8 ml/min) 3200 0.86 4320 0.08 5896 0.14 
High flow rate (1.2 ml/min) 3450 0.78 3548 0.12 4100 0.11 
Less wavelength (205 nm) 3525 0.45 3896 0.45 4752 0.86 
High Wavelength (215 nm) 4272 0.52 3868 0.53 5962 0.86 
Less organic phase composition (-5%)  3984 0.68 3796 0.63 4635 0.86 
High organic phase composition (+5%) 3582 0.67 3863 0.45 3785 0.86 
Less pH variation (-0.2)  3985 0.73 3981 0.58 3868 0.86 
High pH variation (+0.2) 4584 0.59 3789 0.67 4589 0.86 
 
 
Fig. 45: Chromatogram for flow plus 
 
 
Fig. 46: Chromatogram for flow minus 
 
 
Fig. 47: Chromatogram for org plus 
 
Fig. 48: Chromatogram for org minus 
 
 
Fig. 49: Chromatogram for wave plus 
 
 
Fig. 50: Chromatogram for wave minus 
Rao et al. 




Fig. 51: Chromatogram for pH plus 
 
Fig. 52: Chromatogram for pH minus
 
Table 14: Results of stability studies 
Stability  % assay  % deviation 
Initial 100.2 0.00 
6 h 100.8 0.06 
12 h 100.4 0.02 
18 h 100.3 0.01 
24 h 100.5 0.03 
 
Solution stability 
Sample solutions were analysed initially to 24 h at different intervals 
of time at room temperature and the results were recorded. The % 




Fig. 53: Chromatogram for stability initial 
 
 
Fig. 54: Chromatogram for stability 6 h 
 
 
Fig. 55: Chromatogram for stability 12h 
 
Fig. 56: Chromatogram for stability 18 h 
 
 
Fig. 57: Chromatogram for stability 24 h 
 
CONCLUSION 
Stability indicating RP-HPLC method was developed and validated 
for the simultaneous estimation of diethylcarbamazine citrate, 
guaiphenesin and chlorpheniramine maleate in pharmaceutical 
formulations as per ICH guidelines. The developed method was 
found to be accurate, precise and reliable with %RSD less than 2%. 
Therefore, the developed method is simple, accurate, precise and 
robust. The present method was found to be stability indicating as 
the degradation of drug substance was between 5-20%. Finally, this 
method can be used for better analysis of pharmaceutical 
formulations of diethylcarbamazine citrate, guaiphenesin and 
chlorpheniramine maleate drug. 
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